Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01VZE
|
|||
Drug Name |
PMID25435285-Compound-16
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
ELI LILLY AND COMPANY
|
|||
Structure |
Download2D MOL |
|||
Formula |
C17H16Cl2N4O5S
|
|||
Canonical SMILES |
C1=CC(=C(C=C1COC2C(C3C(C3C2(C(=O)O)N)C(=O)O)SC4=NC=NN4)Cl)Cl
|
|||
InChI |
1S/C17H16Cl2N4O5S/c18-7-2-1-6(3-8(7)19)4-28-13-12(29-16-21-5-22-23-16)9-10(14(24)25)11(9)17(13,20)15(26)27/h1-3,5,9-13H,4,20H2,(H,24,25)(H,26,27)(H,21,22,23)/t9-,10-,11-,12-,13+,17+/m0/s1
|
|||
InChIKey |
QHBLXVIRCXAIGL-WNAOHANSSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Antagonist | [1] |
Metabotropic glutamate receptor 3 (mGluR3) | Target Info | Antagonist | [1] | |
Target's Patent Info | Metabotropic glutamate receptor 2 (mGluR2) | Target's Patent Info | [1] | |
Metabotropic glutamate receptor 3 (mGluR3) | Target's Patent Info | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Glutamatergic synapse | ||||
Cocaine addiction | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Ionotropic glutamate receptor pathway | ||||
Metabotropic glutamate receptor group II pathway | ||||
Reactome | G alpha (i) signalling events | |||
Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.